Humacyte has announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in haemodialysis have been accepted for oral presentation at the Charing Cross (CX) Symposium (19–22 April, online).
On 17 February 2021, Alpha Healthcare Acquisition Corp, a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed US$175 million PIPE financing agreement.
The presentation will include five-year outcomes on patients who completed the prospective Phase 2 trial and continued routine dialysis utilising the HAV for access to the bloodstream. The results are supportive of Humacyte’s ongoing development program in AV access which includes a Phase 3 trial in AV access to enable haemodialysis in which patients are randomized to receive either an HAV or an autogenous fistula, the current standard of care.
The details of the presentation are as follows:
Title: Update on bioengineered grafts for vascular access
Date / time: Tuesday 20 April, 14:00–19:30 GMT (9:00–14:30 ET)
Presenting author: Jeffrey Lawson, chief surgical officer, Humacyte
The CX Symposium is the leading global vascular symposium that brings together more than 4,000 vascular specialists from nearly 80 countries to discuss vascular and endovascular controversies. For more information, visit www.cxsymposium.com.